Index

Note: Page numbers in bold refer to Glossary items

12-step facilitation (TSF) programs, 371

abnormal behavior, 510
  definition of, 2–3
abnormal psychology, 510
  definition of, 2–7

abnormality
  challenge of defining, 2–7
  cultural relativism, 5–7, 512

abnormality diagnosis
  use of labels to control or silence others, 6–7

acceptance
  in client-centered therapy, 52
  acceptance and commitment therapy (ACT), 60, 369–76

acetylcholine, 36

actigraphs, 236

active listening, 51

actualizing tendency, 50

acute stress disorder (ASD), 147–48, 510
  biological models and treatment, 149–51
  impact of traumatic events, 147–48
  models, 148–58
  risk factors for developing, 157–58
  treatments, 148–58

adaptive functioning, 458–59, 464–65, 510

addiction, 340

Addyi, 271

adjustment disorder, 138–41, 510
  definition of, 139
  diagnostic overview, 139
  prevalence, 140, 517
  symptoms and description, 139–40
  trajectory, 140
  treatments, 140–41

adoPTION studies, 40

adrenal glands, 37–38

aggression
  violent video games and, 332–33

agonist drugs, 36–37

agoraphobia, 104–6, 510
  case study (Sara Benincasa), 97–98, 105–6
  diagnostic overview, 103–14
  models and treatments, 105–10
  prevalence, 105
  symptoms and description, 105
  trajectory, 105

alcohol use disorder, 344–47, 510
  12-step program (Alcoholics Anonymous), 371
  alcohol withdrawal symptoms, 345
  case study (Buzz Aldrin), 346, 367
  delirium tremens (DT), 345, 512
  diagnostic overview, 345
  effects of alcohol consumption, 91–92
  models and treatments, 367–71, 468–69
  prevalence, 346–47
  symptoms and description, 346–51, 466–67
  symptoms of intoxication and withdrawal, 350
  trajectory, 347

Alcoholics Anonymous
  12-step program, 371

algoria, 418

alprazolam, 43, 114, 119

Alzheimer’s disease, 471–75
  case study (Barbara (B) Smith), 474–75
  diagnostic overview, 472
  early-onset Alzheimer’s, 473
  prevalence, 473
  symptoms and description, 472–73
  trajectory, 473

Ambien, 248

American Law Institute Test (1955)
  (ALI Rule), 497–98, 510

American Psychiatric Association
  (APA), 85
  treatment guidelines for
  schizophrenia, 434–35

American Psychological Association
  (APA)
  Rule on the insanity defense (1983), 498

amitriptyline, 194, 196, 270

amobarbital, 348

amylal, 348

anabolic steroids, 364

Anafrenil, 194

anger
  cultural differences in expression of, 6

anhedonia, 418–19

anorexia nervosa, 300–3, 510
  binge-eating/purging type, 301, 510
  definition of, 300–1
  diagnostic overview, 300
  medical problems associated with, 300–1
  models and treatments, 304–11
  prevalence of, 301–3
  restricting type, 301, 510
  symptoms and description, 294–301
  trajectory, 301–3

Antabuse, 368–69

antagonist drugs, 36–37

anteror cingulate cortex, 129

antianidrogens, 281

aniconvulsants
  use in bipolar disorders, 198

antidepressants, 193–97
  considerations when choosing
  medication for a client, 196–97
  development of, 16–17

© in this web service Cambridge University Press & Assessment
antidepressants (cont.)
monoamine oxidase inhibitors (MAOIs), 193–94
selective serotonin reuptake inhibitors (SSRIs), 194–95, 518
serotonin-norepinephrine reuptake inhibitors (SNRIs), 195–96, 518
studies of effectiveness and tolerance, 196–97
tricyclic antidepressants, 194, 519
antisocial personality disorder, 331, 389–91, 510
case study (Ian Brady), 402–3
diagnostic use of brain scans, 397
models and treatments, 333–34
anxiety, 510
effects of lavender, 107–8
anxiety disorders, 98–99
body dysmorphic disorder (BDD), 124–25, 511
definition of anxiety, 98
excoriation disorder, 127–28, 513
fear, 98, 513
fight, flee, or freeze response, 99, 132, 514
generalized anxiety disorder, 116–21, 514
hoarding disorder, 125–27, 514
in the DSM, 98
incidence of, 98–99
obsessive-compulsive disorder (OCD), 122–24, 516
panic attacks, 110–11, 516
panic disorder, 112–15
phobias, 100–10, 517
sources of anxiety, 98
stress, 98
taijinkyofu sho (TKS), 109
trichotillomania, 127–28, 519
worry, 98, 519
anxiety sensitivity, 115, 510
anxiolytics. See sedative-hypnotic–anxiolytic-related disorders
atipamezole, 333
Asendin, 194
asexuality, 256
assertive community therapy, 435, 510
assessment. See clinical assessment
asylums, 12–13, 510
asylum reform movement, 13–15
ataque de nervios (attack of the nerves), 115
atomoxetine, 333
attention deficit/hyperactivity disorder (ADHD), 443–49, 510
biological models and treatments, 445–48
case study (Jessica McCabe), 441–42, 445
cognitive behavioral models and treatments, 445–48
definition of, 443
diagnostic overview, 444
EndeavorRx game, 445–48
medications, 445–48
models, 445–49
multiperspective models and treatment, 449
neurodiversity, 449–50
presentations of, 444
prevalence of, 444–45
sociocultural models and treatments, 448
symptoms and description, 443–44
trajectory, 444–45
treatments, 445–49, 468–69
attention-seeking behavior
histronic personality disorder, 392–93
atypical antipsychotics, 431, 510
autism spectrum disorder, 450–57, 510
biological models and treatment, 453–55
cognitive-behavioral models and treatment, 454–55
definition of, 450
diagnostic overview, 451
levels of severity, 452
medications, 454–55
models, 453–56
multiperspective models and treatment, 456
neurodiversity, 449–50
prevalence of, 452–53, 456–57
sociocultural models and treatment, 455–56
symptoms and description, 450
trajectory, 452–53
treatments, 453–56
vaccines and autism, 456–57
autogynephilia, 275
autonomic nervous system, 227
avalance, 271
aversion therapy, 369
aversive conditioning, 56
avoidant personality disorder, 403–5, 510
models and treatments, 407–9
avolition, 418
barbiturates, 347–48
symptoms of intoxication and withdrawal, 350
BDMS (bondage, discipline, dominance, submission, and sadism/masochism), 280–81
Beck Depression Inventory, 73
Beck, Aaron, 59–60, 202
Beers, Clifford, 13
behavioral addictions, 365–67
behavioral exposure technique, 130, 510
behavioral genetics, 40
behavioral medicine, 224, 229, 510
behavioral perspective, 53–57, 510
assessment of, 56–57
behavioral theory, 54
behavioral therapies, 54–56
multiperspective approach, 65–66, 516
role of learning, 53–54
behavioral therapies, 54–56
aversive conditioning, 56
classical conditioning, 54–56, 511
counter-conditioning, 54–55
exposure therapy, 55–56, 513
operant conditioning, 56, 516
positive reinforcement, 56
systematic desensitization, 55–56
virtual reality therapy, 55–56
Belsomra, 248
Berm Sex Role Inventory (BSRI), 182
benzodiazepines, 106, 114, 118–19, 151, 348
symptoms of intoxication and withdrawal, 350
binge-eating disorder, 293–95, 511
definition of, 293
diagnostic overview, 294
models and treatments, 304–11
prevalence, 295
problems associated with, 294
symptoms and description, 293–94
trajectory, 295
biofeedback, 227, 511
biological perspective, 32–44
assessment of, 44
biological treatments, 41–44
biological vulnerability concept, 41–42
Index

endocrine system, 37
genetic influences and psychopathology, 37–39
genetics research methods, 39–41
multiperspective approach, 65–66
nature-nurture debate, 37
nervous system, 31–37
twin studies, 40–41
biological psychology, 32
biological theories of psychopathology, 7–8, 511
biomedical treatments, 15, 41–44
biomedical therapies, 42, 511
deep brain stimulation (DBS), 44
non-medication techniques, 43–44
psychosurgery, 43
psychotropic medications, 42–43
transcranial magnetic stimulation (TMS), 43–44
vagus nerve stimulation (VNS), 44, 519
biomedical therapies, 42
bipolar disorders, 184–88, 511
anticonvulsant medications, 198
bipolar I disorder, 184–85, 511
bipolar II disorder, 185, 511

Case study (Andy Behrman), 171
cyclothymic disorder, 185–86, 512
DSM definition, 172–73
manic depression, 187–88
models, 188–207
mood episodes, 184
prevalence, 186–87
specifiers for, 180–81
trajectories, 186–87
treatments, 188–207

Bly, Nellie (pen name of Elizabeth Cochrane), 13
body dysmorphic disorder (BDD), 122, 125
diagnostic overview, 125
heritability, 125
models and treatments for, 128–32
plastic surgery and, 130
prevalence, 125
symptoms and description, 124–25

Body mass index (BMI), 291–92, 511
borderline personality disorder, 391–92, 511

Case study (Marsha Linehan), 379, 394, 400
models and treatments, 333–34

Botox, 270
Boulder model, 20–21
brain anatomy, 33–35
amygdala, 34
cerebral cortex, 35
cerebrum, 34–35
forebrain, 33–35
frontal lobes, 35
hippocampus, 34
hypothalamus, 34
limbic system, 34
nucleus accumbens, 34
occipital lobes, 35
parietal lobes, 35
structure and functions of neurons, 35–37
temporal lobes, 35
thalamus, 33
brain scans
diagnostic use in personality disorders, 397
bremelanotide, 271
Breuer, Josef, 16, 221
brief psychotic disorder, 423, 511
models and treatments, 427–38
Brown, Joyce
civil commitment, 488–92
right to refuse treatment, 505, 518
bulimia nervosa, 296–300, 511
binges, 296–97
bulimic trap (cycle of bulimia), 297–98
case study (Stephanie Armstrong), 289–304
compensatory behaviors, 297, 512
definition of, 296, 488
diagnostic overview, 297
models and treatments, 304–11
prevalence of, 298–99, 488–89
Russell’s sign, 297
symptoms and description, 294–96
trajectory, 298–99
vomiting, 297
bullying
social anxiety disorder and, 103–4, 519

Bynes, Amanda, 258
Cade, John, 197
caffeine excess
symptoms of, 80
caffeine intoxication, 351
callous-unemotional type of conduct disorder, 329, 511
cannabis use disorder, 358–60
Cannabis sativa ( hemp plant), 358–59, 511
diagnostic overview, 360
effects of cannabis use, 358–60
legal aspect of cannabis use, 360
models and treatments, 367–71
prevalence of, 360
symptoms and description, 351–60
tetrahydrocannabinol (THC), 358–59
 carbamazepine, 198
case studies, 22
Andy Behrman (bipolar disorder), 171
Anthony Kiedis (opioid use disorder), 357–58, 367
Barbara (B) Smith (Alzheimer’s disease), 474–75
Buzz Aldrin ( alcohol use disorder), 346, 367
Daniel M’Naghten (insanity defense), 487–88
Demi Lovato ( substance use disorder), 339–40, 367
Elyn Saks (schizophrenia), 415, 427–28
Fletcher Wortmann (obsessive-compulsive disorder), 124, 128–29
Gloria Szymanski, 31, 44, 49–50, 52–53, 57, 61
Ian Brady (antisocial personality disorder), 402–3
Jazz Jennings (gender diversity), 253–54, 259
Jennifer Traig (illness anxiety disorder), 213–14, 223
Jessica McCabe (ADHD), 441–42, 445
Joseph (kleptomania), 321, 324
Lori Schiller (schizoaffective disorder), 425–26, 428
madness of King George III, 1–2, 71
Marsha Linehan (borderline personality disorder), 379, 394, 400
Michael (conduct disorder), 317
Mike Birbiglia (REM sleep behavior disorder), 246–47
Sara Benincasa (agoraphobia), 97, 105–6
case studies (cont.)
Stephanie Armstrong (bulimia nervosa), 289–304
TJ Brennan (PTSD), 137, 141–48
Tom Daley (eating disorder), 302, 304
catatonia, 418
categorical approach to classification of disorders, 83–84
catharsis, 45
Catholic church, 11
Catholic Inquisition
view on deviant behavior, 10
Celexa, 195
central sleep apnea, 241
cerebral cortex, 35
cerebrum, 34–35
Charcot, Jean-Martin, 16
Christian Scientists, 229
chromosomes, 38–39
chronic traumatic encephalopathy (CTE), 476–78, 511
Cialis, 271
circadian rhythm sleep-wake disorders, 242–43, 511
citalopram, 195
civil commitment, 511
case of Joyce Brown, 490, 505
criteria for, 488–89
dangerousness to self and others, 490, 512
definition of, 488
grave disability, 489–90, 514
legal definition of mental illness, 489
parses patriae policy, 489–90
prevalence of, 488
process of, 490–92
Project Help, New York City, 489–90
classical categorical approach to diagnosis, 511
classical conditioning, 54–56
classification systems, 83–85, 511
classical categorical approach, 83–84
definition of, 83
Diagnostic and Statistical Manual of Mental Disorders (DSM), 85–90
dimensional approach, 84
eye history of, 85
International Classification of Diseases (ICD), 85
need for a standardized approach to diagnosis, 83
prototypical approach, 84
client-centered therapy, 51–52, 511
acceptance, 52
empathy, 52, 513
genuineness, 52
phenomenological approach, 52
clinical assessment, 511
challenges of, 80
characteristics of accurate assessments, 72–73
clinical interviews, 73–75, 511
clinical observation of behavior, 78–80
definition of, 72
forms of, 73–81
influence of cultural bias, 80
intake report, 80–81, 515
limitations of, 80
mental status examination (MSE), 75, 515
neuroimaging, 77–78
neuropsychological tests, 77–78, 516
personality inventory, 77, 517
physical examination, 80
presenting problem, 73, 517
process of, 72
projective tests, 75–77
psychological tests and inventories, 73–77
racial bias in clinical decision making, 205
reliability of a measurement, 72, 518
standardization of clinical testing, 72–73
symptoms questionnaires, 75, 519
validity of a measurement, 72, 519
clinical depression. See major depressive disorder
clinical interviews, 73–75
limitations of, 74–75
semi-structured interviews, 74
structured interviews, 73–74
unstructured interviews, 74
clinical observation of behavior, 78–80
naturalistic observation, 78–79
self-monitoring by clients, 79–80
clinical psychologists, 20–21, 511
clinical research model, 19–21, 511
clomipramine, 194
clonazepam, 114
cocaine, 352–53
withdrawal symptoms, 80

Cochrane, Elizabeth, 13
codine, 355
eating disorders (CBT-ED), 308–9
for insomnia (CBT-I), 248
for psychosis (CBT-p), 432–33
perspective, 57–61, 511
assessment of, 61
cognitive theory, 57–59
cognitive therapies, 59–61, 511
exploratory styles, 58–59
external locus of control, 58
internal locus of control, 58
learned helplessness, 58
multiperspectival approach, 65–66
optimism, 58–59
pessimism, 58–59
cognitive processing therapy (CPT), 154
cognitive therapies, 59–61
acceptance and commitment therapy (ACT), 60
dialectical behavior therapy (DBT), 60, 512
rational emotive therapy, 60
third-wave cognitive approaches, 59–60
See also cognitive behavioral therapy (CBT)
cognitive triad, 202
commitment (for treatment), 488, 511
community mental health services, 14–15
comorbid conditions, 82, 512
compensatory behaviors, 297
competence to stand trial, 492–94, 512
compulsions, 422, 512
computerized tomography scan (CT scan), 78, 512
conditional positive regard, 51
cognitive disorder, 329–32, 512
biological models and treatment, 333
callous-unemotional type, 329, 511
case study (Michael), 317
cognitive-behavioral models and treatment, 333–34
definition of, 317–18, 329
diagnostic overview, 325–30
models, 333–35
multiperspectival models and treatment, 334–35
parent management training (PMT), 333–34, 517
prevalence of, 330–31
sociocultural models and treatment, 334
symptoms and description, 327–29
trajectory, 330–31
treatments, 333–35
video games and aggression in children, 332–33
confidentiality, 503, 512
confounding variables, 24, 512
conjunct family therapy, 62
continuous positive airway pressure (CPAP), 247, 512
continuum, 3, 512
couples therapy, 62–63, 206
COVID-19 pandemic, 91, 98, 139, 218
impact on eating disorders, 309
impact on substance use, 340
impact on those with Cluster A personality disorders, 388
impact on those with Cluster B personality disorders, 401–2
impact on those with Cluster C personality disorders, 408–9
crazy
avoiding use of the term, 422
Creutzfeldt–Jakob disease (CJD), 478
cultural bias, 76–77
influence on clinical assessment, 80
cultural competency training for therapists, 63
cultural differences
expression of anxiety, 109, 115
cultural norms, 5–7
cultural psychology, 61
cultural relativism, 512
abnormality and, 5–7
differences in expression of grief, 5–6
culture, 512
influence on willingness to talk about symptoms, 6
culture-bound syndromes, 6
cyclothymic disorder, 185–86
Cymbalta, 119, 196
danger, 512
dangerousness to self and others, 5, 490
Dayvigo, 248
deep brain stimulation (DBS), 44, 200
defense mechanisms, 47, 512
deinstitutionalization, 16–17, 512
delayed ejaculation disorder, 267, 512
delirium, 466–69
definition of, 466
diagnostic overview, 466
models, 467–68
prevalence of, 467–68
prevention of, 468
symptoms and description, 466
trajectory, 467–68
treatments, 468
delusional disorder, 422, 512
models and treatments, 427–38
delusions, 417, 512
Delsysid, 361
dementia. See major neurocognitive disorder
denial (defense mechanism), 47
Depakote, 198
dependent personality disorder, 405, 512
models and treatments, 407–9
dependent variables, 23–24, 512
depersonalization-derealization disorder (DPDRD), 163, 512
diagnostic overview, 163
models and treatments, 163–65
depressant drugs, 344–50, 512
alcohol use disorder, 344–47
sedative-hypnotic-antianxiety-related disorders, 347–50
symptoms of intoxication and withdrawal, 350
depression
interpersonal theories of, 178, 204–5
See also major depressive disorder
depressive disorders, 177–83, 512
definition of, 177
disruptive mood dysregulation disorder (DMDD), 182–83, 513
DSM definition, 172–73
major depressive disorder, 178–79, 515
models, 188–207
persistent depressive disorder (PDD), 179–80, 517
premenstrual dysphoric disorder (PMDD), 181–82, 517
prolonged grief disorder, 183, 517
specifiers for, 180–81
treatments, 188–207
derealization, 163, 391, 512
descriptive validity, 72
designer drugs, 364–65
desvenlafaxine, 196
deviance, 3–4
deviate, 3, 512
diagnosis, 81–83, 512
classification systems, 83–85
comorbid conditions, 82
definition of, 81–82
Diagnostic and Statistical Manual of Mental Disorders (DSM), 85–90
early history of classification, 85
early work of Emil Kraepelin, 15
individual differences, 82
International Classification of Diseases (ICD), 85
need for a standardized approach, 83
potential harm of labeling people, 90
stigma and, 90
unexplained health symptoms or complaints, 249–50
use of diagnostic manuals, 82–83
diagnosis of abnormality
deviance, distress, dysfunction, and danger, 3–5
Diagnosis and Statistical Manual of Mental Disorders (DSM) chapters in DSM-5, 89
debate around DSM-5, 89–90
history of development, 85–90
limitations of DSM-5, 89–90
use of specifiers in DSM-5, 89
diagnostic manuals
eye history of, 85
history of development of the DSM, 85–90
International Classification of Diseases (ICD), 85
use of, 82–83
Index

dialectical behavior therapy (DBT), 60, 400
diathesis-stress model, 65, 512
dimensional approach to classification of disorders, 84, 512
diminished capacity defense, 496
diminished emotional expression, 418
discrimination
influence on OCD symptoms, 131
disorganized behavior, 418
disorganized thoughts and speech, 418
disruptive impulse and conduct disorders, 512
disruptive impulse-control and conduct disorders
overview, 318
See also specific disorders
disruptive mood dysregulation disorder (DMDD), 182–83
dissociation, 513
definition of, 160
dissociative amnesia, 162, 513
diagnostic overview, 162
dissociative fugue, 162–63, 513
models and treatments, 163–65
dissociative anesthesics, 364–65
dissociative disorders, 513
biological models and treatments, 164
definition of dissociation, 160
depersonalization-derealization disorder (DPD), 163
dissociative amnesia, 162
dissociative identity disorder (DID), 160–62, 513
experience of possession and, 165
features of, 160
models, 163–65
non-trauma related or fantasy model, 164–65
psychological models and treatments, 164–65
sociocognitive model, 164–65
treatments, 163–65
dissociative fugue, 162–63
dissociative identity disorder (DID), 160–62
alters, 161
diagnostic overview, 162
history of diagnosis, 161–62
models and treatments, 163–65
disthmic episode, 174
distress, 3–4, 98, 513
disulfiram, 368–69
divalproex, 198
Dix, Dorotha Lynne, 13–14
dizygotic (DZ) twins, 40
dNA (deoxyribonucleic acid), 38–39
dopamine, 36
functions of, 307
dopamine hypothesis of schizophrenia, 430, 513
double-blind study design, 24–25, 513
Down syndrome, 461–62, 513
duloxetine, 119, 196
Durham Test (1954), 496–97, 513
duty to protect, 503–4, 513
duty to warn, 503–4, 513
dysfunction, 3–5, 513
dyspareunia, 267–69
dysnomias, 236, 513
eating disorders, 513
anorexia nervosa, 300–3
binge-eating disorder, 293–95
biological models and treatment, 305–8
body mass index (BMI), 291–92
brain circuits involved, 306
brain-imaging studies, 306
bulimia nervosa, 296–300
case study (Stephanie Armstrong), 289–304
case study (Tom Daley), 302, 304
cognitive-behavioral models and treatment, 308–9
definition of, 290–92
fat shaming, 292–93
features of, 289–92
heritability, 305
impact of the COVID-19 pandemic, 309
influence of family, 309–10
influence of social media, 310–11
influence of society, 310
models, 304–11
mortality rates, 291
multiperspective models and treatment, 311
prevalence of, 290–91
role of dopamine, 306–7
role of neurotransmitters, 306–7
role of serotonin, 306–7
role of the hypothalamus, 306–7
sociocultural models and treatment, 309–10
stigma associated with being overweight, 290

treatments, 304–11
types and key features, 312
ecstasy (MDMA), 364
Effexor, 114, 119, 130, 152, 196
go (Freud), 45–47
go dystonic, 380, 513
go psychology, 49
Elavil, 194, 196
electroconvulsive therapy (ECT), 198–99, 513
electroencephalogram (EEG), 77, 513
Elis, Albert, 60
emotion-focused coping, 226
emotional processing theory, 153–54, 519
empathy, 513
cultural relativism and, 6
in client-centered therapy, 52
Emsam, 193
EndeavorRx game, 448
Effexor, 114, 119, 130, 152, 196
ego (Freud), 45–47
go dystonic, 380, 513
go psychology, 49
Elavil, 194, 196
electroconvulsive therapy (ECT), 198–99, 513
electroencephalogram (EEG), 77, 513
Elis, Albert, 60
emotion-focused coping, 226
emotional processing theory, 153–54, 519
empathy, 513
cultural relativism and, 6
in client-centered therapy, 52
Emsam, 193
EndeavorRx game, 448
endocrine system, 37
environment
influence on population genetics, 39
Epidemic Catchment Area Study, 26
epidemiological studies, 25–26
epigenetics, 151
epinephrine, 37
cros (life instinct), 46
escitalopram, 119, 195, 325
eskapetine, 197
eszopiclone, 248
ethical issues
case study (Daniel M’Naghten), 487–88
patients’ rights, 502–6
etiology, 513
treatment related to, 8
eustress, 98
evolutionary adaptations
fear response, 39
excoriation disorder, 122, 127–28
models and treatments for, 128–32
exhibitionistic disorder, 276–77, 513
models and treatments, 281–83
Exner, John, 76
exorcism, 8, 513
experiment, 23–24, 513
experimental group, 24, 513
experimental method, 23–25
experimentor bias, 24–25, 513
exploratory styles, 58–59
exposure therapy, 55–56
external locus of control, 58
extroversion, 390–91
eye movement desensitization and
reprocessing (EMDR) therapy, 158–59
face validity, 72
factitious disorder, 216–17, 513
factitious disorder imposed on another, 217
Fallon, James, 397
Falret, Jean-Pierre, 187
family
  influence on eating disorders, 309–10
  family-focused therapy, 206–7
  family studies, 39–40
  family systems therapy, 206
  family therapy, 62–63, 206–7, 309–10
  fat shaming, 292–93
  fear, 98
  fear response, 39
  female orgasmic disorder, 266, 267, 272, 513
female sexual interest/arousal disorder, 264, 514
  Feminist Ecological model, 120
  fetal alcohol spectrum disorder, 463–64
  fetishistic disorder, 274–75, 514
  models and treatments, 281–83
  Fetita, 196
  fight, flee, or freeze response, 37, 99
  generalized anxiety disorder and, 117–18
  symptoms of, 132
  See also fight, flee, or freeze response
  fixation (Freud), 47
  flat or restricted affect, 418
  fibanserin, 271
  fluoxetine, 44, 114, 130, 152, 308, 325
  fluvoxamine, 130
  Food and Drug Administration (FDA), 42
  forebrain, 33–35
  Foster, Jodie, 497
  Fragile X syndrome, 462, 514
  free association, 48
  Freud, Sigmund, 15–16, 119, 221
  assessment of the psychodynamic
  perspective, 49–50
  defense mechanisms, 47
  personality theory, 45–46
  psychodynamic therapies, 47–49, 517
  psychosocial stages of development, 46–47
  theory of personality development, 46–47
  views of women, 49
  frontal lobes, 35
  frontotemporal neurocognitive disorder, 475, 514
  frotteuristic disorder, 277–79, 514
  models and treatments, 281–83
  functional magnetic resonance imaging
  (fMRI), 78, 514
  functional neurological symptom
disorder, 219–21
  GABA (gamma-aminobutyric acid), 36
  GABA neurotransmitter system, 118
  gambling disorder, 365–67, 514
  diagnostic overview, 366
  prevalence of, 367
  symptoms and description, 351–66
  trajectory, 367
  gamma hydroxybutyrate (GHB), 365
gay panic defense, 496
gender
  distinction from sex, 255–56
  social construction of, 283–84
  gender confirmation surgery, 259–60
  gender diversity
    case study (Jazz Jennings), 253–54, 259
  gender dysphoria, 254, 256–57, 514
  biological models and treatments, 259–60
  models and treatments, 259–62
  prevalence, 257–58
  psychological models and treatments, 260–62
  symptoms and clinical description, 257
  trajectory, 257–58
  gender expression, 255, 514
  gender identity, 254–55, 514
  misgendering, 258–59
  gender pronouns, 258–59
  gender reveal parties, 255–56
  Gender Unicorn, 74
  gender variations, 256–57
gene expression
  effects of trauma, 150–51
  role of methylation, 150–51
  generalized anxiety disorder, 116–21
  biological models and treatment, 117–19
  cognitive and behavioral models and treatment, 119–20
  diagnostic overview, 117
  Feminist Ecological model, 120
  fight, flee, or freeze response, 117–18
  heritability of, 117
  hypervigilance, 121
  medications for, 118–19
  models, 117–21
  multiperspective models and treatment, 121
  predisposing factors, 121
  prevalence, 117
  protective behaviors, 121
  psychodynamic models and treatment, 119
  sociocultural models and treatment, 120–21
  symptoms and description, 116–17
  trajectory, 117
  treatments, 117–21
  genetic model of PTSD, 150–51
  genetics
  chromosomes, 38–39
  dominant genes, 39
  environmental influences on populations, 39
  influence on psychopathology, 37–39
  nature-nurture debate, 37
  polygenic traits, 39
  principles of genetic inheritance, 38–39
  recessive genes, 39
  role of DNA, 38–39
  genetics research
  adoption studies, 40
  family studies, 39–40
  heritability estimate, 40
  methods, 39–41
  Minnesota Study of Twins Reared Apart (MISTRA), 40–41
  twin studies, 40–41
  genito-pelvic pain/penetration disorder, 267–69, 514
  gender variations, 73–74
  genuineness
    in client-centered therapy, 52
  Geodon, 43
  George III, King
  madness of, 1–2, 71
Index

- glands, 37–38
- glove anesthesia, 219
- grave disability, 489, 514
- grief
  - cultural differences in expression of, 5–6
  - group therapy, 64, 514
  - guilty but mentally ill (GBMI), 499–500, 514
- Gull, William, 301
- hair-pulling disorder. See trichotillomania
- Haldol, 430, 468
- hallucinations, 417, 514
- hallucinogen, 514
- hallucinogen-related disorders, 361–63
  - definition of hallucinogen, 361
  - diagnostic overview, 362
  - models and treatments, 367–71
  - prevalence of hallucinogen use, 363
  - psychedelic drugs, 361
  - symptoms and description, 351–62
- haloperidol, 430, 468
- head trauma, 476–78
- health
  - influence of personality, 224–25
  - health psychology, 224–28, 514
- heritability estimate, 40
- heroin, 355
- Hinckley, John, Jr.
  - attempted assassination of President Ronald Reagan, 497–99
- hippocampus, 34
- Hippocrates of Kos, 9, 85
- historical views of abnormality
  - 18th and 19th centuries, 13–16
  - Age of Discovery, 10–13
  - ancient times, 8–9
  - asylum reform movement, 13–15
  - asylums, 12–13
  - biological treatments, 15
  - Catholic church, 11
  - Catholic Inquisition, 10
  - establishment of community mental health services, 14–15
  - Europe in the Middle Ages, 9–10
  - Greek era, 9
  - Hippocrates of Kos, 9
  - humors, 9, 514
  - mental hygiene movement, 13–15, 515
  - moral treatment, 13–15, 516
- psychoanalytic theory, 15–16
- Renaissance period, 9–10
- theories of psychopathology, 7–8
- use of hypnosis, 16
- witch hunts, 11
- histrionic disorders, 15
- histrionic personality disorder, 392–93
- models and treatments, 394–402
- HIV, 476
- hoarding disorder, 122, 125–27
- diagnostic overview, 126
- models and treatments for, 128–32
- prevalence, 127
- symptoms and description, 125–27
- trajectory, 127
- Hoffman, Albert, 361
- homosexuality, 256, 273–74
- hormone therapy, 271
- hormones, 37
- hospital hopper syndrome, 216
- Human Genome Project, 150
- Human Sexual Inadequacy (Masters and Johnson, 1970), 269
- humanistic approach
  - actualizing tendency, 50
  - client-centered therapy, 51–52
  - effects of conditional positive regard, 51
  - human need for positive regard, 50–51
  - humanistic therapy, 51–52
  - internal wise mind, 50
  - self-regard, 50–51
  - unconditional positive regard, 50–51
  - work of Carl Rogers, 50–52
- humanistic perspective, 50–53
- actualizing tendency, 50
- assessment of, 52–53
- humanistic approach, 50–51
- multiperspective approach, 65–66
- humors, 9
- Huntington’s disease, 476, 514
- Hurricane Hugo (1989), 153
- hypersonomolence disorders, 238–39, 514
- hypervigilance, 121, 142, 148
- hypnagogic hallucinations, 238
- hypnosis, 16, 45
- hypnotics. See sedative-hypnotic-anxiolytic-related disorders
- hypochondria, 217
- hypocretin, 239
- hypomanic episode, 175–76, 514
- hypothalamic pituitary adrenal (HPA) axis, 149, 151
- hypothalamus, 34, 149
- functions of, 306–7
- hypothyroidism, 80
- hysteria, 16, 219, 221
- id (Freud), 45–47
- illness anxiety disorder, 217–18, 514
  - case study (Jennifer Traig), 213, 223
- impulsive, 514
- immune system
  - immunosuppression related to stress, 227
- impulse-control disorders, 514
  - biological models and treatment, 324–25
  - cognitive-behavioral models and treatment, 325
  - definition of, 317–19
  - intermittent explosive disorder, 319–22, 515
  - kleptomania, 321–23, 515
  - models, 324–26
  - multiperspective models and treatment, 326
  - pyromania, 318–23, 518
  - sociocultural models and treatment, 325–26
  - treatments, 324–26
- impulses, 514
- incentive sensitization theory of addiction, 368
- incidence
  - definition of, 25
  - independent variables, 23–24, 514
  - informed consent, 502–3, 515
- inhalant use, 363
- insanity defense, 494–501
- American Law Institute Test (1955)
  - (ALI Rule), 497–98
- APA Rule (1983), 498
  - case study (Daniel M’Naughten), 487–88
- concerns about, 498–99
- diminished capacity, 496
- Durham Test (1954), 496–97
- gay panic defense, 496
- gender bias, 500–1
- guilty but mentally ill (GBMI), 499–500
- irresistible impulse test (1834), 496, 515
M’Naghten Rule (1843), 487–88, 496, 515
not guilty by reason of insanity (NGRI), 495–96, 516
public perceptions of, 498–500
rules of, 496–98
state laws, 501
Twinkie Defense, 496
insomnia, 236–38, 515
cognitive behavioral therapy (CBT-I), 248
insulin treatment, 15
intake report, 80–81
intellectual development disorder (IDD), 458–65, 514
adaptive functioning, 459
biological models and treatment, 461–64
definition of, 458
diagnostic overview, 459
Down syndrome, 461–62
fetal alcohol spectrum disorder, 463–64
Fragile X syndrome, 462
intellectual functioning, 75, 458–59, 464, 515
intelligence testing (IQ), 458–59
IQ (intelligence quotient) range, 460
levels of disability, 459–60
models, 461–65
neurodiversity, 449–50
phenylketonuria (PKU), 463
prevalence of, 460–74
psychological models and treatment, 464
sociocultural models and treatment, 464–65
symptoms and description, 458–60
treatments, 461–65
intellectual disability. See intellectual
development disorder
intellectual functioning, 515
intelligence testing (IQ), 458–59
Intermezzo, 248
intermittent explosive disorder, 319–22
definition of, 319
diagnostic overview, 319–25
models and treatments, 324–26
prevalence, 320–21
symptoms and description, 320–25
trajectory, 320–21
types of behavior, 320
internal locus of control, 58
internal wise mind, 50
International Classification of Diseases (ICD), 85
interpersonal and social rhythm therapy (IPSRT), 207, 515
interpersonal psychotherapy, 205–6, 515
interpersonal theories of depression, 204–5
intradimensional reliability, 72
intersexuality, 255, 515
introversion, 390–91
involuntary hospitalization. See civil commitment
irresistible impulse test (1834), 496, 515
Jackson v Indiana (1972), 493
Japan
taijinkyofu sho (TKS), 109
Jehovah’s Witnesses, 229
Johnson, Virginia, 263, 269
ketamine, 197, 365
Khedezla, 196
kleptomania, 321–23
case study (Joseph), 321, 324
diagnostic overview, 323
models and treatments, 324–26
prevalence of, 323
symptoms and description, 321–27
trajectory, 323
Klonopin, 114
Koch, Ed, 490
Kraepelin, Emil, 15, 84, 187
Krafft-Ebing, Richard von, 279–80
labeling people
stigma and, 90
Lamictal, 43, 198
lamotrigine, 43, 198
lavrander
effects on anxiety, 107–8
learned helplessness, 58, 202–3, 225
learning theory, 368
legal issues
case study (Daniel M’Naghten), 487–88
civil commitment, 488–92
competence to stand trial, 492–94
grave disability, 489–90
insanity defense, 494–501
legal definition of mental illness, 489
not guilty by reason of insanity (NGRI), 495–96
patients’ rights, 502–6
lemborexant, 248
leuprorelin, 259
Levitra, 270
levomilnacipran, 196
Lewy body disease, 476, 515
Lexapro, 119, 195
limbic system, 34, 118
lisdexamfetamine, 308
lithium, 197–98, 325
long-acting injectable antipsychotics (LAs), 432
Louder, 130
lunatic
problematic term, 10
Lunesta, 248
Lupron, 259
Luvox, 130
lysergic acid diethylamide (LSD), 361–62
M’Naghten Rule (1843), 496, 515
magnetic resonance imaging (MRI), 78, 515
major depressive disorder, 515
burden of disease, 178
prevalence of, 178–79
symptoms and diagnosis, 178
major depressive episode, 173, 515
major neurocognitive disorder, 470–78
male hypoactive sexual desire disorder, 265–66, 515
malingering, 215–16, 515
managed care, 515
managed-care system, 18
mania, 515
definition of, 174
manic depression, 187–88
manic episode, 174–75, 515
Marquis de Sade, 279
masochism, 279–81
Masters, William, 263, 269
meal support, 515
measurement
reliability of, 72
standardization of testing protocols, 73
validity of, 72
mechanism of action (MOA), 515
medical conditions
psychological factors affecting, 224–27
psychological models and treatments, 227–29
medications
brand-name medications, 42–43
development of, 16–17
generic medications, 42–43
placebo effect, 42
psychotropic medications, 42–43
melatonin, 232, 515
treatment of sleep disorders, 237–38
mental health professionals, 18–20
mental hygiene movement, 13–15
mental illness
legal definition of, 489
myth of (Szasz), 6–7
mental institutions
Wyatt Standards, 504, 519
mental status examination (MSE), 75
mescaline, 361
Mesmer, Franz Anton, 15–16
meta-analysis, 25, 515
methadone, 355
methamphetamine, 353
methylation, 515
role in gene expression, 150–51
methylphenidate, 44, 239, 333
mild neurocognitive disorder, 470, 515
Milk, Harvey, 496
Minnesota Multiphasic Personality Inventory (MMPI), 77
Minnesota Study of Twins Reared Apart (MISTRA), 40–41
minorities
control by diagnosis of abnormality, 6–7
mirtazapine, 196
misgendering, 258–59
modafinil, 239, 247
modern mental health care, 16–20
clinical psychologists, 20–21
counseling psychologists, 20
deinstitutionalization, 16–17
development of medications, 16–17
managed-care system, 18
masters level therapists, 21
mental health professionals, 18–20
Psychiatric Doctors of Nursing Practice (DNPs), 20
psychiatrists, 18–20
monoamine hypothesis of depression, 189, 516
monoamine oxidase inhibitors (MAOIs), 193–94
monozygotic (MZ) twins, 40
mood disorders, 516
behavioral models, 201
behavioral therapies, 202
biological models, 188–92
biological treatments, 180–93
bipolar disorders, 172–73, 184–88
case study (Andy Behrman), 171
cognitive models, 202–3
cognitive therapy (CBT), 203
deep brain stimulation (DBS), 200
definition of, 129–30
definition of mood, 172
depressive disorders, 172–73, 177–83
electroconvulsive therapy (ECT), 198–99
influence of stressful events, 200–1
manic depression, 187–88
medications for, 193–98
models, 188–207
mood episodes, 173–76
non-medication biological treatments, 180–98
psychological models and treatments, 200–3
sociocultural models, 203–5
sociocultural treatments, 205–7
specifiers for, 180–81
transcranial magnetic stimulation (TMS), 199–200
treatments, 188–207
vagus nerve stimulation (VNS), 200
mood episodes, 173–76
disthymic episode, 174
hypomanic episode, 175–76
major depressive episode, 173
manic episode, 174–75
moral treatment, 13–15
morphine, 355
mortality rate, 25
multiperspective approach, 65–66
diathesis-stress model, 65
reciprocal-gene environment model, 65, 518
multiple personality disorder. See dissociative identity disorder (DID)
Munchausen’s disorder, 216
Muscone, George, 496
Myers, Charles, 145–46
naloxone, 164
naltrexone, 130, 325
Narcan, 164
narcissistic personality disorder, 393–95, 516
models and treatments, 394–402
narcolepsy, 238–39, 516
Nardil, 193
nasogastric feeding tube, 516
National Commission on Mental Hygiene, 85
National Football League (NFL)
recognition of chronic traumatic encephalopathy (CTE) risk for players, 478
naturalistic observation of behavior, 78–79
nature-nurture debate, 37–38
negative correlation, 23, 516
negative symptoms (of psychosis), 418, 421, 431, 516
Nembutal, 348
Neo-Freudians, 16
nervous system, 31–37
autonomic nervous system, 37
brain anatomy, 33–35
central nervous system, 32–37
neural communication, 35–37
neuron structure and functions, 35–37
neurotransmitters, 36–37
parasympathetic nervous system, 37
peripheral nervous system, 32, 37
somatic nervous system, 37
sympathetic nervous system, 37
neural communication, 35–37
neurocognitive disorder due to Alzheimer’s disease, 516
neurocognitive disorders, 469–70, 516
Alzheimer’s disease, 471–75
case study (Barbara (B) Smith), 474–75
cases of, 471
chronic traumatic encephalopathy (CTE), 476–78
Creutzfeldt-Jakob disease (CJD), 478
delirium, 466–69
dementia. See major neurocognitive disorder
differentiating, 482
distinction from neurodevelopmental disorders, 442
frontotemporal neurocognitive disorder, 475
head trauma, 476–78
HIV, 476
Huntington’s disease, 476
Lewy body disease, 476
major neurocognitive disorder, 470–78
mild neurocognitive disorder, 470 models, 478–82
Parkinson’s disease, 476, 517
Pick’s disease, 475
Prion disease, 478, 517
treatments, 478–82
vascular neurocognitive disorder, 475, 519
neurodevelopmental disorders, 516
attention deficit/hyperactivity disorder (ADHD), 443–49
autism spectrum disorder, 450–57
case study (Jessica McCabe), 441–42, 445
distinction from neurocognitive disorders, 441–42
intellectual developmental disorder, 458–65
neurodiversity, 449–50
neurodiversity, 449–50
neurogenesis, 199, 516
neuroimaging, 77–78
computerized tomography scan (CT scan), 78
electroencephalogram (EEG), 77
functional magnetic resonance imaging (fMRI), 78
magnetic resonance imaging (MRI), 78
positron emission tomography (PET scan), 78, 517
neurons
structure and functions, 35–37
neuropsychological tests, 77–78
neuropsychology, 32
neuroscience, 32
neurotransmitters, 36–37
role in eating disorders, 306–7
nicotine
tobacco use disorder, 352
night terrors, 246, 519
nightmare disorder, 243–45
non-REM (nREM) parasomnias, 244–45
norepinephrine, 36
norplant, 194
not guilty by reason of insanity (NGRI), 495, 516
nucleus accumbens, 34
object relations theory, 49
obession, 122, 516
obsessive-compulsive disorder (OCD), 122–24
behavioral exposure technique, 130
biological models and treatment, 129–30
case study (Fletcher Wortmann), 124, 128–29
cognitive and behavioral models and treatment, 130–31
common themes, 123–24
consequences of trivialization in popular culture, 123
cultural differences, 123–24
definition of a compulsion, 122–23
definition of an obsession, 122–23
diagnostic overview, 122
diagnostic overview, 122
medications for, 129–30
models and treatments for, 128–32
power of words, 123
prevalence, 124
related conditions, 122
sociocultural models and treatment, 131–32
symptoms and description, 122–30
trajectory, 124
obsessive-compulsive personality disorder (OCPD), 404–6
models and treatments, 407–9
obstructive sleep apnea hypopnea syndrome, 240–41
occipital lobes, 35
O’Connor v Donaldson (1975), 504–5
olanzapine, 308
operant conditioning, 56, 368
opioid use disorder, 354–55
case study (Anthony Kiedis), 357–58, 367
definition of opioid, 354–56
diagnostic overview, 356
effects of opioids, 354–56
models and treatments, 367–71
opioid withdrawal symptoms, 355–56
overdose and mortality rates, 355–57
prescription opioids, 355
prevalence of, 355–57
symptoms and description, 356
symptoms of opioid intoxication and withdrawal, 355
types of opioid drugs, 355
opioids, 354, 516
oppositional defiant disorder, 318, 516
biological models and treatment, 333
biological models and treatment, 333–34
definition of, 327
diagnostic overview, 327
models, 333–35
multiperspective models and treatment, 334–35
parent management training (PMT), 333–34
prevalence of, 328
sociocultural models and treatment, 334
symptoms and description, 327
trajectory, 328
treatments, 333–35
video games and aggression in children, 332–33
optimism, 58–59
O’Reilly, Finbar, 137
Osmond, Humphrey, 361
OxyContin, 355
pain
sexual pain disorders, 267–69, 518
pain diagnosis
Women in Pain survey, 214–15
Pamelor, 194
panic attacks, 516
diagnostic overview, 111
related to cocaine withdrawal, 80
symptoms and description, 105, 110–11
See also agoraphobia
panic controlled treatment protocol (PCT), 115
panic disorder, 112–15
anxiety sensitivity, 115
biological models and treatment, 112–14
cognitive behavioral models and treatment, 114–15
diagnostic overview, 112
FDA-approved medications for, 103–14
models, 112–15
prevalence, 112–13
psychodynamic models and treatment, 114
sociocultural models and treatment, 115
symptoms and description, 112
panic disorder (cont.)
- trajectory, 112–13
- treatments, 112–15
panic focused psychodynamic psychotherapy (PFPP), 114, 152
paranoid personality disorder, 382–83, 516
- models and treatments, 385–88
paraphilias, 516
paraphilic disorders, 516
- autogynephilia, 275
- BDSM (bondage, discipline, dominance, submission, and sadism/masochism), 280–81
- biological models and treatments, 281–82
- cognitive-behavioral models and treatments, 282
- definition of, 254
- exhibitionistic disorder, 276–77
- features of, 243–44
- fetishes, 274–75
- frotteuristic disorder, 277–79
- models, 281–83
- multiperspective models and treatments, 283
- pedophilic disorder, 279, 517
- sexual masochism disorder, 279–81, 518
- sexual sadism disorder, 279–81, 519
- sociocultural models and treatments, 282–83
- transvestic disorder, 275–76, 519
- treatments, 281–83
- voyeuristic disorder, 277, 519
parasomnias, 236, 243–46, 517
parasympathetic nervous system, 229
- parens patriae policy, 489
- parent management training (PMT), 333–34
- parietal lobes, 35
- Parkinson’s disease, 476
- Parnate, 193
paroxetine, 43, 114, 119, 130, 152, 164, 195
- patients’ rights, confidentiality, 503
- duty to protect, 503–4
- duty to warn, 503–4
- informed consent, 502
right to refuse treatment, 504–6
- right to treatment, 504, 518
- Paxil, 43, 106, 114, 119, 130, 152, 164
- pedophilic disorder, 279
- models and treatments, 281–83
- pentobarbital, 348
- perfection principle (Freud), 46
- persistent depressive disorder (PDD), 517
- prevalence, 180
- symptoms and diagnosis, 179
- personality
- Freud's theory of, 45–46
- influence on health, 224–25
- type A, 225
- type B, 225
- personality development
- Freud's theory of, 46–47
- personality disorders, 510
- antisocial personality disorder, 389–91
- avoidant personality disorder, 403–5
- borderline personality disorder, 391–92
- case study (Ian Brady), 402–3
- case study (Marsha Linehan), 379, 394, 400
- categories (clusters) of DSM-5r, 380
- Cluster A (odd and eccentric personality disorders), 382–88
- Cluster B (dramatic personality disorders), 389–402
- Cluster C (anxious personality disorders), 403–9
- definition of, 380
- definition of personality, 380
- dependent personality disorder, 405
- diagnostic use of brain scans, 397
- ego-dystonic behaviors, 380
- ego-syntonic behaviors, 380
- environmental influences on development, 397
- features of, 380
- introversion and extroversion, 390–91
- models and treatments for Cluster A disorders, 385–88
- models and treatments for Cluster B disorders, 394–402
- models and treatments for Cluster C disorders, 407–9
- narcissistic personality disorder, 393–95
- obsessive-compulsive personality disorder (OCPD), 406
- paranoid personality disorder, 382–83
- schizotypal personality disorder, 384–85, 518
- types and key themes, 409–11
- personality inventory, 77
- pessimism, 58–59
- peyote, 361
- phencyclidine (PCP), 361–62
- phenelzine, 193
- phenomenological approach. See
- humanistic approach
- phenylketonuria (PKU), 463
- phobias, 100–10
- agoraphobia, 104–6
- biological models and treatments, 106–8
- categories of, 100–5
- cognitive behavioral models and treatment, 108–9
- definition of, 100
- models, 105–10
- multiperspective models and treatment, 110
- phobic acquisition, 108
- psychodynamic models and treatment, 108
- social anxiety disorder, 101–4
- sociocultural models and treatment, 109–10
- specific phobia, 100–2, 519
- treatments, 105–10
- phobic acquisition, 108
- physical examination, 80
- Pick’s disease, 475
- pineal gland, 232
- Pinel, Philippe, 13
- placebo effect, 42
- placebos, 24–25, 517
- plastic surgery
- body dysmorphic disorder (BDD), and, 130
- pleasure principle (Freud), 45–46
- polygraph tests, 77–78
- polysomnography, 235–36
- positive correlation, 23, 517
- positive regard
- human need for, 50–51
- positive reinforcement, 56
- positive symptoms (of psychosis), 416, 421, 424, 430, 517
positron emission tomography (PET scan), 78
possession experience dissociative disorders and, 165
post-traumatic stress disorder (PTSD), 141–47
biological models and treatment, 149–51
biological vulnerability concept, 41–42
case study (TJ Brennan), 137, 141, 148
changing views of the effects of combat trauma, 145–46
cognitive-behavioral models and treatments, 153–54
debate over EMDR therapy, 158–59
definition of, 141
diagnostic overview, 160
impact of traumatic events, 147–48
impacts and risks associated with, 143–44
medications for, 151
models, 148–58
multiperspectival models, 157–58
post-Vietnam syndrome, 146
prevalence, 147
prevalence of exposure to trauma, 143
psychodynamic models and treatments, 152
risk factors for developing, 150–51, 155–58
shell shock and, 145–46
sociocultural models, 155–57
sources of trauma, 141–43
symptoms, 144–45, 165–66
treatments, 148–58
post-Vietnam syndrome, 146
practitioner-scholar model, 21, 517
predictive validity, 72
premature ejaculation, 267, 270, 517
premenstrual dyshoric disorder (PMDD), 181–82
premenstrual syndrome (PMS), 181
presenting problem, 73
prevalence, 517
definition of, 25–26
Prion disease, 478
Pristiq, 196
problematic language
lunatic, 10
problem-focused coping, 226
Project Help, New York City, 490
projection (defense mechanism), 47
projective tests, 75–77
prolonged exposure (PE) technique, 153–54
prolonged grief disorder, 183
prosocial emotions, 330, 517
Protection and Advocacy for Mentally Ill Individuals Act (1988), 504
prototypical approach to classification of disorders, 84, 517
Provigil, 247
Prozac, 44, 106, 114, 130, 152, 195, 308
psilocybin mushrooms, 361
psychiatric disorders, 418
psychodynamic psychotherapy, 108
psychodynamic therapies, 47–49
psychodynamic psychotherapy, 108
psychodynamic therapies, 47–49
free association, 48
psychoanalysis, 48
resistance from the client, 22
short-term psychodynamic therapy, 48–49
psychological conditions not necessarily disorders, 6–7
psychological disorders, 517
definition of, 2
psychological factors affecting medical conditions, 224–27
biological models and treatment, 227
cognitive and behavioral models and treatments, 227–29
psychosis, 518
affective disorders, 518
anhedonia, 418
avolition, 418
chemical dependency, 418
definition of, 518
delusions, 417
diminished emotional expression, 418
dissociation, 518
disorganized behavior, 418
disorganized thoughts and speech, 418
delayed onset, 418
flat or restricted affect, 418
hallucinations, 417
negative symptoms, 418–19
positive symptoms, 416–18
psychosis, 518
psychodynamically oriented therapies, 108
premise of Sigmund Freud, 45–46
psychodynamic psychotherapy, 108
psychodynamic therapies, 47–49
free association, 48
psychoanalysis, 48
resistance from the client, 22
short-term psychodynamic therapy, 48–49
psychotic disorders (cont.)
  brain structural differences, 428–30
  brief psychotic disorder, 423
  case study (Elyn Saks), 427–28
  cognitive-behavioral models and treatment, 427–33
  delusional disorder, 422
  dopamine hypothesis, 430
  effective treatment for schizophrenia, 427
  genetic vulnerability, 428
  long-acting injectable antipsychotics (LAIs), 432
  models, 427–38
  multiperspective models and treatment, 434–35
  neurodevelopmental hypothesis, 428
  schizoaffective disorder, 424, 518
  schizophrenia, 419–21, 518
  Schizophrenia Spectrum and Other Psychotic Disorders (DSM-5tr), 419
  schizotypal disorder, 423–24, 518
  sociocultural models and treatment, 433–34
  treatments, 427–38
  psychotropic medications, 42–43
  pyromania, 318–23, 518
  definition of, 323
  diagnostic overview, 324–27
  models and treatments, 324–26
  prevalence of, 318–24
  symptoms and description, 45–50
  trajectory, 324

quetiapine, 468
rational emotive therapy, 60
Reagan, Ronald
  reality principle (Freud), 46
  reciprocal-gene environment model, 65
recovery
  definition of, 25
  regression (defense mechanism), 47
  reliability of a measurement, 72
  REM parasomnias, 243–45
  REM sleep behavior disorder, 243, 518
  case study (Mike Birbiglia), 246–47
  Remeron, 196
  repression (defense mechanism), 47
  research, 22
  case studies, 22
  correlational research, 22–23
  epidemiological studies, 25–26
  experimental method, 23–25
  genetics research methods, 39–41
  restricting type of anorexia nervosa, 301, 510
  reward deficiency syndrome theory, 368
  right to refuse treatment, 504, 518
  right to treatment, 504, 518
  Risperdal, 468
  risperidone, 333, 468
  Rogers, Carl
    client-centered therapy, 51–52
    humanistic approach, 50–51
  Rorschach Inkblot Test, 76
  Rosenhan pseudo-patient study, 86–87
  Rozerem, 248
  Russell’s sign, 297
  Sacher-Masoch, Leopold von, 280
  sadism, 279–81
  Sakel, Manfred
  schizophrenia, 419
  diagnostic overview, 45–50
  REM sleep behavior disorder, 243, 518
  case study (Lori Schiller), 425–26, 428
  models and treatments, 427–38
  schizotypal personality disorder, 384–85
  models and treatments, 385–88
  scientist-practitioner model, 20–21, 518
  secobarbital, 348
  sexual desire disorders, 510
  sedative drugs, 348
  sedative-hypnotic-antianxiety-related disorders, 347–50
  diagnostic overview, 349
  drug types, 347–48
  features of, 347–48
  prevalence of, 349–50
  symptoms and description, 349
  symptoms of intoxication and withdrawal, 350
  trajectory, 349–50
  self-monitoring by clients, 79
  self-psychology, 49
  self-regard, 50
  selegiline, 193
  self-monitoring by clients, 79–80
  self-psychology, 49
  self-regard, 50–51
  serotonin, 36
  functions of, 306–7
  serotonin-norepinephrine reuptake inhibitors (SNRIs), 114, 130, 195–96, 325
  sertraline, 114, 130, 152, 195, 325
  sex
  biological characteristics in humans, 255
  defining characteristics of, 255
  distinction from gender, 255–56
  sexual arousal disorder, 518
  sexual desire disorders, 518
  sexual dysfunctions, 518
  biological models and treatments, 269–71
  cognitive-behavioral models and treatments, 271–72
  definition of, 254
disorders of sexual desire and arousal, 264–67
dyspareunia, 267–69
ejaculation disorders, 266–67
erectile disorder, 266
female orgasmic disorder, 266
female sexual interest/arousal disorder, 120
genito-pelvic pain/penetration disorder, 267–69
hormone-related problems, 269–70
male hypoactive sexual desire disorder, 265–66
medications for, 270–71
models, 269–72
multiperspectival models and treatment, 272
nocturnal penile tumescence (NPT) assessment, 270
orgasm disorders, 266–67
related to medical conditions, 270
sexual pain disorders, 267–69
sexual response cycle, 263–64, 518
sociocultural models and treatments, 272
treatments, 269–72
vaginismus, 267–69
vulvodynia, 267–69
sexual masochism disorder, 279–81
models and treatments, 281–83
sexual orientation, 256, 518
sexual response cycle, 263–64
sexual sadism disorder, 279–81
models and treatments, 281–83
sexuality, 254–56
shaping of behavior, 56
shell shock, 145–46
shock therapy. See electroconvulsive therapy (ECT)
short-term psychodynamic therapy, 48–49
sildenafil, 270–71
silexan, 107
Singer, Helen, 264
Singer, Judy, 449
Skinner, B. F., 56
skin-picking disorder. See excoriation disorder
slavery, 7
sleep, 519
sleep apnea, 239–41, 519
sleep apps, 236
sleep attacks (daytime), 238
sleep eating, 245
sleep paralysis, 243–44
sleep-related breathing disorders, 239–41
sleep-related hypoventilation, 240–42
sleep terrors (night terrors), 246
sleepwalking, 244–45
sociocultural models and treatments, 248
treatments, 247–48
sleepwalking, 244–45
smartphone apps
sleep apps, 236
use for self-monitoring, 80
social anxiety disorder, 101–4
bullying and, 103–4
diagnostic overview, 103
FDA-approved medications for, 106–30
models and treatments, 105–10
prevalence, 103–4
symptoms and description, 102–3
trajectory, 103–4
social media
influence on eating disorders, 310–11
social phobia, 102, 519
See also social anxiety disorder
social psychology, 61
society
influence on eating disorders, 310
sociocognitive model, 164–65
sociocultural perspective, 61–64, 519
assessment of, 64
conjunct family therapy, 62
couples therapy, 62–63
cultural competency training for therapists, 63
family therapy, 62–63
group therapy, 63–64
multiperspectival approach, 65–66
structural family therapy, 62
systems approach, 62–63
somatic symptom and related disorders
biological models and treatment, 222
case study (illness anxiety disorder), 213–14, 223
cognitive and behavioral models and treatment, 223
conversion disorder, 219–21
factitious disorder, 216–17
factitious disorder imposed on another, 217
features of, 214–15
hysteria, 219–50
illness anxiety disorder, 217–18
somatic symptom and related disorders
(cont.)
influences on pain diagnosis, 214–15
malingering, 215–16
medications, 222
models, 221–23
multiperspective models and
treatment, 223
psychodynamic models and
treatment, 222–23
sociocultural models and treatment, 223
somatic symptom disorder, 218–19,
519
treatments, 221–23
somatic symptom disorder, 218–19
Sonata, 248
specific phobia, 100–2
diagnostic overview, 100
forms of, 101
models and treatments, 105–10
prevalence of, 101–3
specifiers, 101
symptoms and description, 100–1
trajectory, 101–3
specifiers (DSM), 519
Spoelstra, Margaret, 457
standardization of clinical testing, 72–73
standardized, 519
Statistical Manual for the Use of
Institutes for the Insane
(1917), 85
Stendra, 271
steroids, 364
stigma
psychological disorder diagnosis and,
90
stimulant, 519
stimulant-induced psychosis, 351
stimulant use disorders, 351–54
caffeine intoxication, 351
cocaine, 352–53
definition of a stimulant, 351
diagnostic overview, 353
effects of stimulants, 351
methamphetamine, 353
models and treatments, 367–71
prevalence of, 354
symptoms and description, 351–53
symptoms of stimulant intoxication
and withdrawal, 354
tobacco use disorder, 352
stress, 98
coping strategies for, 225–26
immunosuppression related to, 227
stress response
fight, flee, or freeze response, 99
influence of personality, 224–25
influence on health, 224–25
neuropsychological tests, 77–78
stressful events
influence on mood disorders, 200–1
structural family therapy, 62
Structured Clinical Interview for the
DSM-5 (SCID-5), 74
sublimation (defense mechanism), 47
substance use disorders, 519
12-step program (Alcoholics
Anonymous), 371
addiction, 340
alcohol use disorder, 344–47
biological models and treatments,
367–68
cannabis use disorder, 358–60
case study (Demi Lovato), 339–40,
367
classes of substances, 342–43
cognitive-behavioral models and
treatment, 368–69
corrected substances, 343–44
depressants, 344–50
designer drugs, 364–65
detoxification, 368
development of new illicit drugs,
363
diagnostic criteria for, 341
dissociative anesthesics, 364–65
drug dependence, 365
drug rebound effects, 340
ecstasy (MDMA), 364
features of, 339–41
gamma hydroxybutyrate (GHB), 365
inhalants, 363
ketamine, 365
mechanism of action (MOA) of
psychoactive drugs, 342–43
models, 367–71
multiperspective models and
treatment, 370
non-stigmatizing terminology, 341–42
opiod use disorder, 354–55
psychoactive drug effects by class,
372–74
sedative-hypnotic-anxiolytic-related
disorders, 347–50
sociocultural models and treatment,
369–70
stimulant use disorders, 351–54
synthetic anabolic steroids, 364
tolerance effect, 340
treatments, 367–71
use of psychoactive drugs, 340–41
withdrawal symptoms, 340
superego (Freud), 45–47
supernatural theories of
psychopathology, 7–8, 519
suprachiasmatic nucleus, 223, 519
suvorexant, 248
sympathetic nervous system, 149
tobacco use disorder, 352
treatment, 370
thalamus, 33
thematic apperception test (TAT), 76
Teresa of Avila, 11
tardive dyskinesia, 430–31, 519
Tegretol, 198
telehealth (telemedicine), 91
temporal lobes, 35
teresa of Avila, 11
test-retest reliability, 72
thalamus, 33
Thanatos (death instinct), 46
thematic apperception test (TAT), 76
therapists
cultural competency training, 63
deficit model, 9
masters level therapists, 21
Thomas, Lisy, 90
tobacco use disorder, 352
models and treatments, 367–71
topiramate, 325
triquanillizers, 348
transcranial magnetic stimulation
(TMS), 43–44, 199–200
transgender or gender non-conforming
(TGNC) people, 527, 519
biological models and treatments,
259–60
case study (Jazz Jennings), 253–54,
259
misgendering, 258–59
models and treatments, 259–62
<table>
<thead>
<tr>
<th>Prevalence, 257–58</th>
<th>Psychological models and treatments, 260–62</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms and clinical description, 257</td>
<td></td>
</tr>
<tr>
<td>Trajectory, 257–58</td>
<td></td>
</tr>
<tr>
<td>Transvestic disorder, 275–76</td>
<td></td>
</tr>
<tr>
<td>Models and treatments, 281–83</td>
<td></td>
</tr>
<tr>
<td>Traumatic disorder, 275–76</td>
<td></td>
</tr>
<tr>
<td>Psychological models and treatments, 260–62</td>
<td></td>
</tr>
<tr>
<td>Symptoms and clinical description, 257</td>
<td></td>
</tr>
<tr>
<td>Trajectory, 257–58</td>
<td></td>
</tr>
</tbody>
</table>

**Trauma**

- Definition of, 141–43
- Effects on gene expression, 150–51
- Prevalence of exposure to, 143
- Sources of, 141–43

**Trauma and stressor-related disorders**

- Acute stress disorder (ASD), 147–48
- Adjustment disorder, 138–41
- Post-traumatic stress disorder (PTSD), 141–47

**Treatment**

- Behavioral therapies, 54–56
- Biological treatments, 41–44
- Choice of therapy approach, 91
- Client-centered therapy, 51–52
- Cognitive therapies, 59–61
- Effectiveness of treatments, 91–92
- Features of effective treatments, 93
- Humanistic therapy, 51–52
- Psychodynamic therapies, 47–49
- Psychotherapy, 91–93
- Related to etiology, 8
- Right to refuse treatment, 504, 518
- Right to treatment, 504, 518
- Telehealth (telemedicine), 91
- Trephination, 8–9, 519

**Trichotillomania**

- 122, 127–28, 519

**Tricyclic antidepressants**

- 194, 270

**Tucker, William**

- 13

**Trajectory**

- 257–58

**Transvestic disorder**

- 275–76

**Tranquillizer**

- 193

**Vaccine**

- 270

**Valium**

- 36

**Valproate**

- 198

**Vapin**

- 101

**Venaflon**

- 270

**Venlafaxine**

- 114, 119, 130, 152, 196

**Vibryd**

- 195

**Vilazodone**

- 195

**Vinysetti**

- 271

**Vylasey**

- 308

**Vodafone**

- 91

**Zaleplon**

- 248

**Ziprasidone**

- 43

**Zolpidem**

- 248

**Zoom**

- 91

**Zyprexa**

- 308

**Violence**

- Dangerousness to self and others, 490
- Tendency towards, 3, 5
- Virtual reality therapy, 55–56
- Vitamin D deficiency symptoms, 80
- Von Meduna, Ladislas, 198–99
- Voyeuristic disorder, 277
- Models and treatments, 281–83
- Vulpodynia, 267–69
- Vyvanse, 308
- Walker, Nick, 449
- Weyer, Johan, 11
- White, Dan, 496
- Witch hunts, 11
- Women
  - Freud’s views of, 49
  - Hysteria and, 221
  - Women in Pain survey, 214–15
  - World Mental Health Surveys, 26
  - Worry, 98, 519
  - See also Generalized anxiety disorder
- Wyatt Standards, 504, 519
- Wyatt v Stickney (1972), 504
- Xanax, 43, 114, 119
- Yealland, Louis, 146

**Worry**

- 98, 519

**World Mental Health Surveys**

- 26

**Wyatt Standards**

- 504, 519